Name + Title: Consol Casablanca, Sr. Director Global Client Services

Office location: Barcelona, Spain

Hire date: 1998

Where were you born?  Barcelona, Spain

What did you study at university? I received a bachelor’s degree in English Philology from Barcelona University

Languages spoken: Catalan, Spanish, English and German

If you could learn any language, which would you pick and why? I would like to continue with German. But if I must choose a new one, I would definitely pick Japanese. I like the culture and I would love to challenge myself learning how to write Japanese characters.

What life sciences publications or resources do you recommend? RAPS and attending industries conferences.

What trends are you seeing in the medical device space?

It is becoming a more regulated industry. The existing European medical device directives will be replaced by the recently approved Medical Device Regulation (MDR) and In Vitro Diagnostics Regulations (IVDR). This new regulation is stricter than the previous one and provides a new regulatory framework for this industry.

What are some challenges sponsors or CROs face when conducting clinical trials?  There are several challenges sponsors and CROs face during the global clinical trial process. Here are just a few:

  • There is an increasing demand for clinical trials being carried out in Asian countries, however there are limited resources for some regional and local languages.
  • Ethics committees and Institutional Review Boards not accepting translations of Patient Information Sheets or Institutional Review Boards because of low legibility, causing a delay in the start of the clinical trial in that country or site.
  • Different documents need to be translated or can be kept in English depending on the target country.
  • Patient-reported outcomes need to be perfectly understood in the same way by patients in different countries in order to be able to pool the data across countries.

How can Welocalize Life Sciences can help with these challenges?

With offices all over the world, Welocalize Life Sciences has easy and quick access to almost all possible target groups. Through standardized but flexible translation workflows we can guarantee quality translations even into languages where finding qualified resources seems impossible.

Thorough pre-production, expanded clinical investigation term data bases, translation memories of thousands of approved translated segments, support to translators throughout the life cycle of the projects, technological innovation are only few of the steps we take to guarantee high legibility in our translations.

And, finally, it is important to understand there is more to the translation process than the translation itself. Welocalize Life Sciences resources vary from qualified, experienced medical translators to doctors and healthcare professionals that provide advice and support in all regulatory and legal matters. Moreover, our production team is highly experienced and up to date on all new regulations and industry trends.

What are you most proud of (personally and/or professionally)? I am very proud of creating Nova, my last translation company, and that thanks to the talented team and its work and efforts, it has become part of a multinational company, the 7th largest in the world.

Do you have a bucket list? What is something you are hoping to check off the list soon? Travel to Tanzania is something that has been on my list for a long time. Hopefully, during a summer vacation in the future this dream will come true.